furazolidone has been researched along with Cardiomyopathy, Hypertrophic Obstructive in 1 studies
Furazolidone: A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone acts by gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)
furazolidone : A member of the class of oxazolidines that is 1,3-oxazolidin-2-one in which the hydrogen attached to the nitrogen is replaced by an N-{[(5-nitro-2-furyl)methylene]amino} group. It has antibacterial and antiprotozoal properties, and is used in the treatment of giardiasis and cholera.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gwathmey, JK | 1 |
| Hamlin, RL | 1 |
1 other study available for furazolidone and Cardiomyopathy, Hypertrophic Obstructive
| Article | Year |
|---|---|
Protection of turkeys against furazolidone-induced cardiomyopathy.
Topics: Animals; Cardiomyopathy, Hypertrophic; Digoxin; Furazolidone; Poultry Diseases; Propranolol; Turkeys | 1983 |